Globotriaosylceramide leads to KCa3.1 channel dysfunction: A new insight into endothelial dysfunction in Fabry disease

Cardiovascular Research

Volumn 89, Issue 2, 2011, Pages 290-299

  Park, Seonghee ^a   Kim, Ji Aee ^a   Joo, Ka Young ^a   Choi, Shinkyu ^a   Choi, Eun Nam ^a   Shin, Jung A ^a   Han, Ki Hwan ^a   Jung, Sung Chul ^a   Suh, Suk Hyo ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

Galactosidase A knockout mice; Endothelial dysfunction; Fabry disease; Globotriaosylceramide; KCa3.1 channel

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLCHOLINE; ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 PHOSPHATE; POTASSIUM CHANNEL BLOCKING AGENT; REPRESSOR ELEMENT 1 SILENCING TRANSCRIPTION FACTOR; TRAM 34; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; CERAMIDE TRIHEXOSIDE; KCNN4 PROTEIN, MOUSE; POLYPHOSPHOINOSITIDE; RE1 SILENCING TRANSCRIPTION FACTOR; RE1-SILENCING TRANSCRIPTION FACTOR; REPRESSOR PROTEIN; VASODILATOR AGENT;

ABDOMINAL AORTA; AGED; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FABRY DISEASE; GENE EXPRESSION; INFERIOR CAVA VEIN; KNOCKOUT MOUSE; MOUSE; NONHUMAN; POTASSIUM CHANNELOPATHY; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN FUNCTION; THORACIC AORTA; UPREGULATION; VASODILATATION; VOLTAGE CLAMP; ANIMAL; CELL CULTURE; CELL MEMBRANE POTENTIAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ALPHA-GALACTOSIDASE; ANIMALS; CELLS, CULTURED; CLASS III PHOSPHATIDYLINOSITOL 3-KINASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FABRY DISEASE; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MEMBRANE POTENTIALS; MICE; MICE, KNOCKOUT; PHOSPHATIDYLINOSITOL PHOSPHATES; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRIHEXOSYLCERAMIDES; VASODILATION; VASODILATOR AGENTS;

EID: 78751509194     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq333     Document Type: Article

References (30)

1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967;276: 1163-1167.
2. Zarate YA, Hopkin RJ. Fabry's disease. Lancet 2008;372:1427-1435.
3. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002;81:122-138.
4. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007;28:1228-1235.
5. Shu L, Park JL, Byun J, Pennathur S, Kollmeyer J, Shayman JA. Decreased nitric oxide bioavailability in a mouse model of Fabry disease. J Am Soc Nephrol 2009;20: 1975-1985.
6. Park JL, Whitesall SE, D'Alecy LG, Shu L, Shayman JA. Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membranebased defect. Clin Exp Pharmacol Physiol 2008;35:1156-1163.
7. Ahn SC, Seol GH, Kim JA, Suh SH. Characteristics and a functional implication of Ca2+-activated K+ current in mouse aortic endothelial cells. Pflugers Arch 2004;447: 426-435.
8. Tharp DL, Bowles DK. The intermediate-conductance Ca2+-activated K+ channel (KCa3.1) in vascular disease. Cardiovasc Hematol Agents Med Chem 2009;7:1-11.
9. Chapman H, Ramstrom C, Korhonen L, Laine M, Wann KT, Lindholm D et al. Downregulation of the HERG (KCNH2) K+ channel by ceramide: evidence for ubiquitinmediated lysosomal degradation. J Cell Sci 2005;118:5325-5334.
10. Titievsky A, Titievskaya I, Pasternack M, Kaila K, Tornquist K. Sphingosine inhibits voltage-operated calcium channels in GH4C1 cells. J Biol Chem 1998;273:242-247.
11. Jung SC, Han IP, Limaye A, Xu R, Gelderman MP, Zerfas P et al. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci USA 2001;98:2676-2681.
12. Suh SH, Vennekens R, Manolopoulos VG, Freichel M, Schweig U, Prenen J et al. Characterisation of explanted endothelial cells from mouse aorta: electrophysiology and Ca2+ signalling. Pflugers Arch 1999;438:612-620.
13. Manolopoulos VG, Liu J, Unsworth BR, Lelkes PI. Adenylyl cyclase isoforms are differentially expressed in primary cultures of endothelial cells and whole tissue homogenates from various rat tissues. Biochem Biophys Res Commun 1995;208:323-331.
14. Nilius B, Schwartz G, Oike M, Droogmans G. Histamine-activated, non-selective cation currents and Ca2+ transients in endothelial cells from human umbilical vein. Pflugers Arch 1993;424:285-293.
15. Lauf PK, Misri S, Chimote AA, Adragna NC. Apparent intermediate K conductance channel hyposmotic activation in human lens epithelial cells. Am J Physiol Cell Physiol 2008;294:C820-832.
16. Cheong A, Bingham AJ, Li J, Kumar B, Sukumar P, Munsch C et al. Downregulated REST transcription factor is a switch enabling critical potassium channel expression and cell proliferation. Mol Cell 2005;20:45-52.
17. Srivastava S, Li Z, Lin L, Liu G, Ko K, Coetzee WA et al. The phosphatidylinositol 3- phosphate phosphatase myotubularin-related protein 6 (MTMR6) is a negative regulator of the Ca2+-activated K+ channel KCa3.1. Mol Cell Biol 2005;25:3630-3638.
18. Srivastava S, Choudhury P, Li Z, Liu G, Nadkarni V, Ko K et al. Phosphatidylinositol 3-phosphate indirectly activates KCa3.1 via 14 amino acids in the carboxy terminus of KCa3.1. Mol Biol Cell 2006;17:146-154.
19. Shu L, Murphy HS, Cooling L, Shayman JA. An in vitro model of Fabry disease. J Am Soc Nephrol 2005;16:2636-2645.
20. von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991;324:395-399.
21. Guo J, Massaeli H, Xu J, Jia Z, Wigle JT, Mesaeli N et al. Extracellular K+ concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell lines. J Clin Invest 2009;119:2745-2757.
22. Choi S, Park S, Liang GH, Kim JA, Suh SH. Superoxide generated by lysophosphatidylcholine induces endothelial nitric oxide synthase downregulation in human endothelial cells. Cell Physiol Biochem 2010;25:233-240.
23. Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, Schiffmann R et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 2008;95:163-168.
24. Samavati L, Monick MM, Sanlioglu S, Buettner GR, Oberley LW, Hunninghake GW. Mitochondrial KATP channel openers activate the ERK kinase by an oxidantdependent mechanism. Am J Physiol Cell Physiol 2002;283:C273-C281.
25. Merla R, Ye Y, Lin Y, Manickavasagam S, Huang MH, Perez-Polo RJ et al. The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation. Am J Physiol Heart Circ Physiol 2007;293:H1918-H1928.
26. Si H, Heyken WT, Wolfle SE, Tysiac M, Schubert R, Grgic I et al. Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca2+-activated K+ channel. Circ Res 2006;99:537-544.
27. Brahler S, Kaistha A, Schmidt VJ, Wolfle SE, Busch C, Kaistha BP et al. Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation 2009;119:2323-2332.
28. Kleinert J, Dehout F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C et al. Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens 2006;19:782-787. (Pubitemid 44107697)
29. Liang GH, Kim JA, Seol GH, Choi S, Suh SH. The Na+/Ca2+ exchanger inhibitor KB-R7943 activates large-conductance Ca2+-activated K+ channels in endothelial and vascular smooth muscle cells. Eur J Pharmacol 2008;582:35-41.
30. Wei AD, Gutman GA, Aldrich R, Chandy KG, Grissmer S, Wulff H. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev 2005;57:463-472. (Pubitemid 43036436)